The French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) and patient associations, notably the AFM-Telethon, conducted a multicenter study during the first wave of the Covid-19 pandemic in France, from March 25, 2020 to May 11, 2020. The results reveal :
a lower prevalence of Covid-19 in neuromuscular patients followed by the Filnemus network than in the general population (0.0017 versus 0.0026);
a higher hospitalization rate than that of the general population, but a slightly lower mortality (0.11 vs 0.14);
a preponderance of diabetes, high blood pressure and the severity of neuromuscular disease, three parameters identified as risk factors for developing a severe form of Covid-19;
an absence of short-term impact of Covid-19 on neuromuscular pathology in 58% of cases.
This is useful data for adapting treatment and vaccine recommendations.
